Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)

Eshraghi A. A., Aranke M., Salvi R., Ding D., Coleman J. K. M., Ocak E., ...Daha Fazla

HEARING RESEARCH, cilt.368, ss.86-91, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 368
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.heares.2018.03.003
  • Dergi Adı: HEARING RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.86-91
  • Ankara Üniversitesi Adresli: Hayır

Özet

There is a growing interest in the auditory community to develop novel prophylactic and therapeutic drugs to prevent permanent sensorineural hearing loss following acute cochlear injury. The jun-N-terminal protein kinase (JNK) pathway plays a crucial role in acute sensory hearing loss. Blocking the JNK pathway using the cell-penetrating peptide D-JNKI-1 (AM-111/brimapitide) has shown promise as both a prophylactic and therapeutic agent for acute cochlear injury. A number of pre-clinical and clinical studies have determined the impact of D-JNKI-1 on acute sensorineural hearing loss. Given the inner-ear selective therapeutic profile, local route of administration, and ability to diffuse across cellular membranes rapidly using both active and passive transport makes D-JNK-1 a promising oto-protective drug. In this review article, we discuss the application of D-JNKI-1 in various auditory disorders as well as its pharmacological properties and distribution in the cochlea. (C) 2018 Elsevier B.V. All rights reserved.